Tokai Pharmaceuticals is focused on developing new treatments for prostate cancer, with lead candidate galeterone (TOK-001), an oral small molecule that combines three mechanisms to disrupt androgen receptor signaling. Galeterone showed clinical activity and was well tolerated in the ARMOR1 Phase 1 dose-finding study (49 patients) completed in 2012. The company is currently evaluating a new oral formulation of galeterone in the ARMOR2 Phase 2 trial across multiple castration-resistant prostate cancer (CRPC) populations. ARMOR2’s primary endpoints are PSA reduction and safety; secondary endpoints include RECIST tumor responses and an extension arm for responders. Tokai plans to use new funding to expand ARMOR2 and to prepare for registration studies. The company is based in Cambridge, Massachusetts and was founded by Apple Tree Partners; it is backed by Apple Tree Partners and Novartis Venture Funds. Tokai Pharmaceuticals is focused on developing new treatments for prostate cancer, with its lead candidate galeterone (TOK-001). Galeterone is an oral small molecule that combines three mechanisms of action: androgen receptor antagonism, CYP17 lyase inhibition, and reduction of androgen receptor levels in tumors. The company completed a proof-of-concept Phase 1 ARMOR trial that enrolled 49 patients to evaluate dose, safety and PSA reductions; responders continued on an extension arm. Tokai plans to advance galeterone into Phase 2 clinical development and will use newly raised proceeds to support that work. The company is privately held and based in Cambridge, Massachusetts, and is backed by Apple Tree Partners and Novartis Venture Fund. Management was recently strengthened with the appointment of Martin D. Williams as president and CEO.

Total raised

$59M

Funding rounds

2

Latest round

Series E

Latest activity

May 2013